A citation-based method for searching scientific literature

Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford, Richard Marais. Cell 2004
Times Cited: 2011



Gideon Bollag, James Tsai, Jiazhong Zhang, Chao Zhang, Prabha Ibrahim, Keith Nolop, Peter Hirth. Nat Rev Drug Discov 2012
Times Cited: 454




List of shared articles



Times cited

BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.
Ioannis Tsamis, Georgia Gomatou, Stavroula Porfyria Chachali, Ioannis Panagiotis Trontzas, Vasileios Patriarcheas, Emmanouil Panagiotou, Elias Kotteas. Clin Transl Oncol 2022
0

Recent advances in B-RAF inhibitors as anticancer agents.
Pathan Shahebaaz Khan, Patil Rajesh, Patil Rajendra, Manohar G Chaskar, Arote Rohidas, Sangshetti Jaiprakash. Bioorg Chem 2022
2

High-Content Screening Pipeline for Natural Products Targeting Oncogenic Signaling in Melanoma.
Lara Dürr, Tanja Hell, Maciej Dobrzyński, Alberto Mattei, Anika John, Nathanja Augsburger, Gloria Bradanini, Jakob K Reinhardt, Florian Rossberg, Milos Drobnjakovic,[...]. J Nat Prod 2022
1


Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines.
Cheng-I Lee, Chu-Bin Liao, Chih-Shang Chen, Fen-Ying Cheng, Yu-Hsuan Chung, Yu-Chuan Wang, Sian-Yi Ciou, Wen-Yun Hsueh, Tzu-Hao Lo, Guan-Ru Huang,[...]. Bioorg Chem 2021
0